For Rapid, High-throughput Antibody Measurement in Bioprocess Samples

MADISON, Wis.–BioSystem Development, LLC., a privately held life science analytics company, announces the release of the AssayMAP MAb Titer Assay for measuring antibody product concentrations (or titers) in bioprocess samples.

Antibody titer assays are a critical bottleneck in biotherapeutic process development. Although the current “gold standard” method – protein A affinity HPLC – is reliable, selective, sensitive and precise, its throughput is severely limited to merely 4 – 12 samples an hour. The AssayMAP MAb Titer assay uses exactly the same chemistry as Protein A HPLC with a 100-fold increase in throughput, equivalent analytical performance and no need for specialized instrumentation. AssayMAP cartridges, filled with POROS® MabCapture™ A media from Life Technologies Corporation, offer rapid, small-scale parallel analysis either manually in a spin-column format or on common automation platforms and measure IgG concentration across a wide dynamic range ideally suited for process development without a need for sample dilution.

“This launch is a significant milestone in the evolution of the AssayMAP platform,” said Scott Fulton, founder and CEO. “It is the first assay we adapted to a spin-column format that requires only common lab equipment to perform, making AssayMAP solutions readily available for researchers when investment in new instrumentation platforms is not possible.”

About BioSystem Development

BioSystem Development, LLC, established in 2002, creates, manufactures and markets tools and products to meet the critical and growing analytical needs of pharmaceutical development. The company’s AssayMAP™ platform (based on disposable micro-chromatography cartridges and automation) enables high throughput solutions for bioprocess development, biomarkers and general life science research that reduce development time and increase efficiency.